Skip to main content

KALA BIO, Inc.

corporate_fare Company Profile

KALA BIO, Inc.

KALA·NASDAQ·Life Sciences·CIK 0001479419

KALA BIO, Inc. is a biopharmaceutical company that is transitioning its business focus to evaluate the development of a dedicated, on-premises artificial intelligence (AI) infrastructure platform for the biotechnology industry. The company is currently leveraging its mesenchymal stem cell secretome ("MSC-S") platform to test the development of a scalable AI platform-as-a-service business. This service aims to deploy secure, purpose-built AI systems directly within biotech and pharmaceutical client environments. Historically, KALA BIO was involved in the research, development, and commercialization of therapies for rare and severe eye diseases. Its lead product candidate was KPI-012, an MSC-S therapy acquired from Combangio, Inc. on November 15, 2021. KPI-012 was in clinical development for persistent corneal epithelial defects ("PCED"), a rare corneal healing disorder. Following a Phase 1b clinical trial, an investigational new drug application was accepted by the U.S. Food and Drug Administration ("FDA") in December 2022. In February 2023, the company began its CHASE (Corneal Healing After SEcretome therapy) Phase 2b clinical trial of KPI-012 for PCED. However, by September 2025, the CHASE trial did not meet its primary endpoints, leading KALA BIO to discontinue development of KPI-012 and the MSC-S platform. The company is now evaluating strategic alternatives for its legacy MSC-S assets and utilizing the intellectual property, proprietary biological datasets, and research experience from the clinical trials to develop an AI platform. On March 3, 2026, KALA BIO entered into an exclusive license for the Researgency AI research platform from Younet AI to assess the feasibility of becoming a dedicated AI infrastructure partner for the biotechnology industry.

KALA BIO, Inc. (NASDAQ:KALA) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 34 items for KALA at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-16, rated 8/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 15 rated 8 or above. Recent SEC coverage for KALA spans 8-K, DEF 14A, PRE 14A, 10-Q.

Recent high-impact activity:

  • Nasdaq Panel Grants KALA BIO Continued Listing With $1.00 Bid Cure Deadlines
  • KALA BIO Sets 1-for-30 Reverse Split, Trading Adjusted November 16
  • KALA BIO Cuts Quarterly Net Loss ~90% to $0.8M, Ends Quarter With $7M Cash and No Debt
  • KALA Bio Signs LOI to Acquire $12.7M-Revenue Telehealth Platform for $15M
  • KALA BIO Sets November 3 Vote on Reverse Split Up to 1-for-300 to Regain Nasdaq Compliance

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$0
Net Income
-$26.98M
Diluted EPS
-$3.31
Op. Cash Flow
-$31.99M
Operating Income
-$39.16M
Cash & Equivalents
$7.56M
Debt / Equity
0.00×
Shares Outstanding
27.85M sh
Source: 10-K · filed 2026-04-15 · accession 0001104659-26-043782

Short Interest & Short Volume

1.81 days to cover

FINRA reported short interest of 382,804 shares in KALA as of the October 30, 2026 settlement, a 29.0% decrease from the prior period — about 1.8 days to cover at its recent average daily volume. On November 13, 2026, 66.1% of KALA volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)382,804 shares as of October 30, 2026
Change vs prior period▼ 29.0%
Days to cover1.81 at avg daily volume of 211,044
Daily short volume (FINRA facilities)66.1% of 398,681 shares on November 13, 2026
5-day average short volume56.5%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Dilution Risk

High risk

Filing-implied dilution signals for KALA, detected from its recent SEC filings · based on capital-structure filings through 2026-07-22.

1 recent capital raiseATM program1 shelf registrationreverse split

$250M ATM Program Launched · Massive Potential Dilution

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

Browse all tickers starting with K →
$3.51 -15.71% today
52-week range · as of 2026-11-16 $3.44 – $2865
Market cap
$2.68M
Volume
22.9K (1.9× avg)
3-mo avg 12.2K
Live data · 2026-11-16 18:30 UTC · Market open

show_chartPrice Chart

Loading chart...

feed KALA - Latest Insights

KALA
Nov 16, 2026, 6:02 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $4.49
Real-time Price: $3.51 info
Change: Reverse Stock Split info
Market Cap: $2.684M info
KALA
Nov 12, 2026, 8:00 AM EST
Source: TMX Newsfile
Importance Score:
7
Updated Nov 12, 4:31 PM ET — KALA BIO's certificate of amendment sets the 1-for-30 split effective 4:05 p.m. November 13, 2026, with new CUSIP 483119400 and authorized…
Price at Filing: $0.149
Real-time Price: $3.51 info
Change: Reverse Stock Split info
Market Cap: $2.684M info
KALA
Nov 09, 2026, 8:00 AM EST
Source: TMX Newsfile
Importance Score:
7
Price at Filing: $0.1568
Real-time Price: $3.51 info
Change: Reverse Stock Split info
Market Cap: $2.684M info
KALA
Sep 29, 2026, 7:30 AM EDT
Source: TMX Newsfile
Importance Score:
8
Price at Filing: $0.474
Real-time Price: $3.51 info
Change: Reverse Stock Split info
Market Cap: $2.684M info
KALA
Sep 24, 2026, 4:10 PM EDT
Filing Type: DEF 14A
Importance Score:
7
Price at Filing: $0.5288
Real-time Price: $3.51 info
Change: Reverse Stock Split info
Market Cap: $2.684M info
KALA
Sep 11, 2026, 4:56 PM EDT
Filing Type: PRE 14A
Importance Score:
8
Price at Filing: $0.590
Real-time Price: $3.51 info
Change: Reverse Stock Split info
Market Cap: $2.684M info
KALA
Sep 03, 2026, 8:30 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $0.538
Real-time Price: $3.51 info
Change: Reverse Stock Split info
Market Cap: $2.684M info
KALA
Aug 28, 2026, 6:45 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $0.795
Real-time Price: $3.51 info
Change: Reverse Stock Split info
Market Cap: $2.684M info
KALA
Aug 19, 2026, 4:16 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $0.900
Real-time Price: $3.51 info
Change: Reverse Stock Split info
Market Cap: $2.684M info
KALA
Jul 22, 2026, 6:29 PM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $0.720
Real-time Price: $3.51 info
Change: Reverse Stock Split info
Market Cap: $2.684M info
KALA
Jul 22, 2026, 5:13 PM EDT
Filing Type: 424B5
Importance Score:
9
Price at Filing: $0.7512
Real-time Price: $3.51 info
Change: Reverse Stock Split info
Market Cap: $2.684M info
KALA
Jul 02, 2026, 5:37 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
8
Price at Filing: $1.68
Real-time Price: $3.51 info
Change: Reverse Stock Split info
Market Cap: $2.684M info
KALA
Jun 12, 2026, 4:05 PM EDT
Filing Type: S-3/A
Importance Score:
7
Price at Filing: $2.58
Real-time Price: $3.51 info
Change: Reverse Stock Split info
Market Cap: $2.684M info
KALA
May 16, 2026, 3:14 AM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $2.90
Real-time Price: $3.51 info
Change: Reverse Stock Split info
Market Cap: $2.684M info
KALA
May 15, 2026, 3:30 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $2.96
Real-time Price: $3.51 info
Change: Reverse Stock Split info
Market Cap: $2.684M info
KALA
May 12, 2026, 7:00 AM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $3.80
Real-time Price: $3.51 info
Change: Reverse Stock Split info
Market Cap: $2.684M info
KALA
May 07, 2026, 5:25 PM EDT
Filing Type: S-3
Importance Score:
9
Price at Filing: $0.0838
Real-time Price: $3.51 info
Change: Reverse Stock Split info
Market Cap: $2.684M info
KALA
May 07, 2026, 4:07 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $0.0839
Real-time Price: $3.51 info
Change: Reverse Stock Split info
Market Cap: $2.684M info
KALA
May 07, 2026, 9:08 AM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $0.0929
Real-time Price: $3.51 info
Change: Reverse Stock Split info
Market Cap: $2.684M info
KALA
Apr 15, 2026, 4:05 PM EDT
Source: Wiseek News
Importance Score:
9
Price at Filing: $0.198
Real-time Price: $3.51 info
Change: Reverse Stock Split info
Market Cap: $2.684M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets